USClinicalTrials.govClinical trialPhase 1Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Official record
- Identifier
NCT07090499- Recruiting locations
countries
United StatesCanadaChinaPuerto RicoSpainUnited Kingdom- Interventions studied
- PF-08046876PembrolizumabCisplatinCarboplatin
- Lead sponsor
- Pfizer
- Target enrolment
- 540 participants
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Status
- Recruiting
- First posted
- Jul 29, 2025
- Last updated on the registry
- Oct 1, 2026
- Age
- 18 Years
- Sex
- ALL
- Study contact
- The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.
- Eligibility criteria
Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.
Inclusion Criteria: * 18 years of age or older * Advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas * Measurable disease * ECOG Performance status 0-1 * Part 1: progression or relapse following standard treatments * Part 2: maximum of 2 prior lines of systemic therapy in the advanced setting * Part 3: advanced cancer of the lung or bladder, prior treatment requirements vary by combination therapy group * Resolution of acute effects of prior anticancer therapy to baseline or Grade 1 * Consent to submit required pre-treatment tumor tissue as medically feasible Exclusion criteria: * Received prior treatment with an antibody drug conjugate with a camptothecin-class payload (e.g. sacituzumab govitecan, trastuzumab deruxtecan ) * Active anorexia, nausea or vomiting, and/or signs of intestinal obstruction meeting protocol exclusion * Pulmonary disease meeting protocol exclusion * Other unacceptable abnormalities as defined by protocol * Part 3: Meet contraindications of combination products per protocol and/or local labels
- Indexed under
- Lung Cancer